Cowen and Company’s bluebird bio BLUE Stock Holding History

Cowen and Company’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-332	Closed	-$130K	–	605
2021 Q1	$130K	Buy	+332	New	+$163K	0.01%	302

Other funds holding BLUE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Cowen and Company's BLUE Position: Q2 2021 in Review

Cowen and Company sold out of bluebird bio (BLUE) in Q2 2021, closing a stake of 332 shares — an estimated $130K sold.

Cowen and Company first reported a position in BLUE in Q1 2021 and held it in 1 quarter. The position peaked at $130K in Q1 2021. 232 funds tracked by Wall St. Rank hold BLUE as of Q2 2021.

Cowen and Company reported no remaining bluebird bio position as of Q2 2021 after selling out during the quarter.
Cowen and Company sold 332 bluebird bio shares in Q2 2021, an estimated $130K.
Cowen and Company first reported a position in bluebird bio in Q1 2021 and held it in 1 quarter.
Cowen and Company's bluebird bio position peaked at $130K in Q1 2021.
232 funds tracked by Wall St. Rank held bluebird bio as of Q2 2021.

Based on Cowen and Company's 13F filing for Q2 2021, filed 13 Aug 2021.